CJC-1295 isn't stocked on pharmacy shelves in Giba or virtually any local market — it's a research compound distributed through a dedicated online market. The benefit of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers more rigorous quality data than any physical store could provide. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. Use this guide to verify vendor quality systematically — the standards covered in this guide are universal across all research contexts.
CJC-1295 Mechanisms Explained
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Giba studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate CJC-1295 Vendors
Assessing CJC-1295 vendors starts with the COA: locate the batch-specific certificate before placing an order, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone provides no identity confirmation. Red flags in CJC-1295 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that omit endotoxin testing. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.
Order CJC-1295 — ships to Giba
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human use by the FDA or comparable health authorities — all information here is educational. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. Bacterial endotoxin contamination is the primary safety concern specific to research peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. The research literature on CJC-1295 should be studied thoroughly before designing any protocol — study approaches, dose levels, and measured endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
